Abstract
New drugs offer options for patients with drug-resistant tuberculosis (DR-TB). We describe four individuals with DR-TB in KwaZulu-Natal, South Africa, with prior exposure to clofazimine who would benefit from access to delamanid (DLM). Without DLM, individual options are limited, and there is a risk of resistance amplification and both community and nosocomial spread of DR-TB.
MeSH terms
-
Adult
-
Antitubercular Agents / therapeutic use*
-
Drug Resistance, Multiple, Bacterial*
-
Drug Therapy, Combination
-
Extensively Drug-Resistant Tuberculosis / diagnosis
-
Extensively Drug-Resistant Tuberculosis / drug therapy*
-
Extensively Drug-Resistant Tuberculosis / microbiology
-
Female
-
Health Services Accessibility
-
Humans
-
Male
-
Nitroimidazoles / therapeutic use*
-
Oxazoles / therapeutic use*
-
South Africa
-
Treatment Outcome
-
Tuberculosis, Multidrug-Resistant / diagnosis
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Tuberculosis, Multidrug-Resistant / microbiology
-
Young Adult
Substances
-
Antitubercular Agents
-
Nitroimidazoles
-
OPC-67683
-
Oxazoles